Literature DB >> 21874559

Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.

Martin K Church1.   

Abstract

OBJECTIVE AND
DESIGN: Comparison of bilastine and cetirizine in inhibiting skin wheal and flare responses over 24 h.
SUBJECTS: Twenty-one healthy male volunteers (aged 19-44 years). TREATMENT AND METHODS: Volunteers were randomised to receive single oral doses of 20 or 50 mg bilastine, 10 mg cetirizine or placebo before provocation of wheal and flare responses to 100 mg/ml histamine by skin prick 1.5, 4, 8, 12 and 24 h later.
RESULTS: There were no significant differences between overall inhibitions of wheal or flare by 20 mg bilastine and 10 mg cetirizine. Bilastine was faster in onset than cetirizine, inhibitions of wheal and flare at 1.5 h being 89 ± 3 versus 44 ± 14% (P = 0.011) and 85 ± 4 versus 45 ± 14% (P = 0.016), respectively (Student's t test). At 1.5 h, both wheals and flares were inhibited by >70% in 11/12 volunteers taking bilastine and 3/11 taking cetirizine (P = 0.003, Fisher's exact test). There were no significant differences between the drugs at later times. Bilastine 50 mg had a longer duration of action than bilastine 20 mg.
CONCLUSIONS: Both 20 mg bilastine and 10 mg cetirizine are effective and of long duration in reducing histamine-induced wheal and flare responses, the major difference between the two drugs being the more rapid onset of action of bilastine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874559     DOI: 10.1007/s00011-011-0373-y

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  24 in total

1.  A neural pathway for itch.

Authors:  M Schmelz
Journal:  Nat Neurosci       Date:  2001-01       Impact factor: 24.884

Review 2.  Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.

Authors:  Martin K Church
Journal:  Expert Opin Drug Saf       Date:  2011-08-11       Impact factor: 4.250

3.  Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity.

Authors:  Reyes Corcóstegui; Luis Labeaga; Ana Innerárity; Agustin Berisa; Aurelio Orjales
Journal:  Drugs R D       Date:  2005

4.  Intravital microscopic studies on acute mast cell-dependent inflammation.

Authors:  J Raud
Journal:  Acta Physiol Scand Suppl       Date:  1989

5.  Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.

Authors:  G F Clough; P Boutsiouki; M K Church
Journal:  Allergy       Date:  2001-10       Impact factor: 13.146

6.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.

Authors:  Cuiping Chen; Elizabeth Hanson; John W Watson; Jae S Lee
Journal:  Drug Metab Dispos       Date:  2003-03       Impact factor: 3.922

7.  EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.

Authors:  T Zuberbier; R Asero; C Bindslev-Jensen; G Walter Canonica; M K Church; A M Giménez-Arnau; C E H Grattan; A Kapp; M Maurer; H F Merk; B Rogala; S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; H Schünemann; P Staubach; G A Vena; B Wedi
Journal:  Allergy       Date:  2009-10       Impact factor: 13.146

8.  Correlations between histamine-induced wheal, flare and itch.

Authors:  U Darsow; J Ring; E Scharein; B Bromm
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

9.  Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.

Authors:  T Zuberbier; A Oanta; E Bogacka; I Medina; F Wesel; P Uhl; I Antépara; I Jáuregui; R Valiente
Journal:  Allergy       Date:  2009-10-23       Impact factor: 13.146

10.  Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.

Authors:  K J Denham; P Boutsiouki; G F Clough; M K Church
Journal:  Inflamm Res       Date:  2003-10       Impact factor: 4.575

View more
  10 in total

Review 1.  New therapies for allergic rhinitis.

Authors:  Fulvio Braido; Francesca Sclifò; Matteo Ferrando; Giorgio Walter Canonica
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

Review 2.  Bilastine: in allergic rhinitis and urticaria.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

3.  Bilastine: new insight into antihistamine treatment.

Authors:  Erminia Ridolo; Marcello Montagni; Laura Bonzano; Cristoforo Incorvaia; Giorgio Walter Canonica
Journal:  Clin Mol Allergy       Date:  2015-04-15

4.  Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.

Authors:  Ole D Wolthers
Journal:  Biomed Res Int       Date:  2013-07-14       Impact factor: 3.411

5.  Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.

Authors:  Michinori Togawa; Hidetoshi Yamaya; Mónica Rodríguez; Hirotaka Nagashima
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

6.  Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine.

Authors:  Reggie Bosma; Zhiyong Wang; Albert J Kooistra; Nick Bushby; Sebastiaan Kuhne; Jelle van den Bor; Michael J Waring; Chris de Graaf; Iwan J de Esch; Henry F Vischer; Robert J Sheppard; Maikel Wijtmans; Rob Leurs
Journal:  J Med Chem       Date:  2019-07-05       Impact factor: 7.446

7.  Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.

Authors:  Mario Sánchez-Borges; Riccardo Asero; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan A Bernstein; G Walter Canonica; Richard Gower; David A Kahn; Allen P Kaplan; Connie Katelaris; Marcus Maurer; Hae Sim Park; Paul Potter; Sarbjit Saini; Paolo Tassinari; Alberto Tedeschi; Young Min Ye; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

8.  Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria.

Authors:  Belen Sadaba; Jose Ramon Azanza; Almundena Gomez-Guiu; Raquel Rodil
Journal:  Ther Clin Risk Manag       Date:  2013-05-03       Impact factor: 2.423

Review 9.  Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.

Authors:  Xue Yan Wang; Margaret Lim-Jurado; Narayanan Prepageran; Pongsakorn Tantilipikorn; De Yun Wang
Journal:  Ther Clin Risk Manag       Date:  2016-04-13       Impact factor: 2.423

Review 10.  Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement.

Authors:  Ralph Mösges; Dennis Lip Yen Lee; Jovilia Abong; Bella Siasoco; Steven Kw Chow; Jern-Lin Leong; Harvinder Singh; S Kuljit; Benjamin Campomanes
Journal:  Asia Pac Allergy       Date:  2016-01-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.